FLAURA: First-Line OS Benefit Confirmed For Advanced EGFR-Mutated NSCLC
Front-line osimertinib offers a significant overall survival advantage for patients with advanced EGFR-mutated non-small-cell lung cancer compared with gefitinib or erlotinib...
ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.